Primary pulmonary hypertension

Friday, 12 April 2002


M. Leeman (Brussels, Belgium)  


Actelion Switzerland
Aventis France
GlaxoSmithKline Belgium
Therabel Belgium

Primary pulmonary hypertension: from bench to bedside

Session I

Abstract no
Chair M. Leeman (Brussels, Belgium)  
9.30 – 10.10 Genetic aspects
S. Adnot (Paris, France)
10.10 – 10.50 Epidemiological aspects
G. Simonneau (Paris, France)
10.50 end of session I  
10.50 – 11.15 coffee break  

Session II

Chair M. Leeman (Brussels, Belgium)  
11.15 – 11.55 Medical therapeutic aspects
W. Seeger (Giessen, Germany)
11.55 – 12.05 Alprostadil and NO immediately after lung transplantation: effects on pulmonary vasculature 
D. Pranger, P. Bulpa, J. Jamart, E. Installé and P. Evrard (Yvoir, Belgium)
12.05 – 12.15 Endogenous nitric oxide opposes the pulmonary vasoconstricting effect of endothelins in vivo
I. Hubloue, D. Biarent, G. Bejjani, F. Kerbaul, R. Naeije, and M. Leeman (Brussels, Belgium)
12.15 – 12.25 Haemodynamic comparison of Urapidil with other therapies for primary pulmonary hypertension
Y. Laurent, P. Bulpa, J. Jamart, S. Casel, E. Installé, and P. Evrard (Yvoir, Belgium)
12.25 – 12.35 Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
S. Huez, J.L. Vachiéry, and R. Naeije (Brussels, Belgium)
12.35 – 12.45 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension
Y. Laurent
, P. Bulpa, P. Binamé, H. Rahir, E. Installé, and P. Evrard (Yvoir, Belgium)
12.45 – 12.55 Effect of nitric oxide synthase-gene transfer on endothelial function of isolated rat pulmonary artery rings
L. Jiang
, M. Cauberghs, P. Pokreisz, S. Janssens, M. Demedts, and M. Delcroix (Leuven, Belgium)
12.55 end of workshop 15